A late-stage study for Gilead Science's drug to treat fibrosis symptoms associated with nonalcoholic steatohepatitis didn't meet its goal of treating disease symptoms last week.
Three key details:
1. The drug, selonsertib, failed to improve NASH symptoms in the study, which took place two months after a previous study during which the drug failed. NASH is a nonalcoholic fatty liver disease that can cause fatigue, nausea and weight loss.
2. The trial involved patients with compensated cirrhosis, an advanced form of NASH.
3. In a statement, John McHutchison, chief scientific officer and head of research and development for Gilead Sciences, said: "We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways involved in the pathogenesis of this disease."